Lilly's Weight-Loss Drug Works for Nearly Half of Trial Patients

Eli Lilly's retatrutide helped 45% of trial patients lose at least 30% of their body weight over 80 weeks. That's a significant share, not just an average pulled by a few big winners. Insurance companies use this kind of data—how many patients actually see real results—to decide whether to cover a drug. It's often the deciding factor.